Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study
Siu Hing Lo, Rohini Sharma, Charlotte Costentin, Daniel Aggio, Suki Shergill, F. Colaone, Victoria K. Brennan, Vincenzo A Straccia, Ion Agirrezabal, Andrew Lloyd
Abstract
The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living in Europe. Overall survival (OS) was the most important attribute, closely followed by risk of diarrhea and hypertension, and other adverse event (AE) risks. Patients were willing to trade OS to reduce AE risks. While less important than OS and AEs, patients also preferred shorter waiting times, and one-off administration of selective internal radiation therapy and oral tablets over intravenous infusions. Although patients placed the most value on extending OS, they were willing to forego OS to avoid risk of treatment-related AEs, to maintain their quality of life.